Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

COGT Cogent Biosciences, Inc.

交易中 03-18 13:46:10 EDT

34.80

-0.62

-1.75%

最高35.42	最低34.27	成交量43.68万
今开35.36	昨收35.42	日振幅3.25%
总市值56.48亿	流通市值49.76亿	总股本1.62亿
成交额1,520万	换手率0.31%	流通股本1.43亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"COGT","market":"US","secType":"STK","nameCN":"Cogent Biosciences, Inc.","latestPrice":34.8,"timestamp":1773855967598,"preClose":35.42,"halted":0,"volume":436770,"delay":0,"changeRate":-0.017504234895539372,"floatShares":142999640,"shares":162308800,"eps":-2.16,"marketStatus":"交易中","change":-0.62,"latestTime":"03-18 13:46:10 EDT","open":35.36,"high":35.42,"low":34.27,"amount":15196988.483099999,"amplitude":0.032468,"askPrice":34.82,"askSize":215,"bidPrice":34.79,"bidSize":222,"shortable":3,"etf":0,"ttmEps":-2.16,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1522296000000,"exchange":"NASDAQ","adjPreClose":35.42,"preHourTrading":{"tag":"盘前","latestPrice":35.06,"preClose":35.42,"latestTime":"09:17 EDT","volume":4346,"amount":155227.55964,"timestamp":1773839840986,"change":-0.36,"changeRate":-0.010164,"amplitude":0.052513},"postHourTrading":{"tag":"盘后","latestPrice":35.42,"preClose":35.42,"latestTime":"18:08 EDT","volume":117122,"amount":4148466.28,"timestamp":1773785318215,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.320794,"impliedVol":0.9003,"impliedVolPercentile":0.6335},"requestUrl":"/m/hq/s/COGT","defaultTab":"news","newsList":[{"id":"1189701379","title":"Cogent Biosciences宣布FDA受理Bezuclastinib治疗非晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1189701379","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189701379?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:38","pubTimestamp":1773664686,"startTime":"0","endTime":"0","summary":"Cogent Biosciences Inc近日宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的上市申请。根据FDA的处方药使用者付费法案（PDUFA），该药物的审评截止日期定为2026年12月30日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","COGT","BK4139"],"gpt_icon":0},{"id":"1135972760","title":"Cogent Biosciences早盘大涨7.2% 旗下罕见病药物申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1135972760","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135972760?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:37","pubTimestamp":1773664656,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.股价在盘前交易中强势上扬7.2%，此前美国食品药品监督管理局（FDA）已正式受理其针对一款罕见病治疗药物的新药申请，并将启动审评流程。这一关键监管进展为该公司核心产品的商业化之路扫清了首个重要障碍，显著提振了市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1106712714","title":"Cogent Biosciences宣布FDA受理Bezuclastinib治疗非晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1106712714","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106712714?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:37","pubTimestamp":1773664627,"startTime":"0","endTime":"0","summary":"Cogent Biosciences宣布，美国食品药品监督管理局（FDA）已正式受理其新药Bezuclastinib用于治疗非晚期系统性肥大细胞增多症（Nonadvsm）的新药申请。这一重要进展标志着该药物在监管审批流程中迈出了关键一步，为非晚期系统性肥大细胞增多症患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","BK4505"],"gpt_icon":0},{"id":"2612417452","title":"Cogent Biosciences, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612417452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612417452?lang=zh_cn&edition=full","pubTime":"2026-02-18 02:44","pubTimestamp":1771353866,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日02时44分，Cogent Biosciences, Inc.股票出现异动，股价大幅拉升5.01%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，Polaryx Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Cibus, Inc.涨幅较大，Ensysce Biosciences, Inc.、Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.较为活跃，换手率分别为796.97%、99.06%、90.71%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Ensysce Biosciences, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为81.33%、74.28%、39.89%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021802442695415c92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021802442695415c92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4139","BK4505"],"gpt_icon":0},{"id":"1190388912","title":"Cogent Biosciences公布近期业务亮点及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1190388912","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190388912?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:02","pubTimestamp":1771333325,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.（简称：Cogent Biosciences）近日披露了公司近期的业务进展概要，并同步发布了2025年第四季度及全年的财务报告。此次公布的内容涵盖了公司在关键业务领域的动态以及详细的财务数据，为投资者和市场观察者提供了全面的运营与财务状况更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1151108523","title":"Cogent Biosciences递交Bezuclastinib治疗非晚期系统性肥大细胞增多症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1151108523","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151108523?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:05","pubTimestamp":1767099958,"startTime":"0","endTime":"0","summary":"Cogent Biosciences宣布，已正式提交Bezuclastinib用于治疗非晚期系统性肥大细胞增多症的新药申请。这一重要进展标志着该创新疗法向临床应用迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","COGT"],"gpt_icon":0},{"id":"1161798638","title":"Cogent Biosciences公布Bezuclastinib在晚期系统性肥大细胞增多症患者中的Apex试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1161798638","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161798638?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:37","pubTimestamp":1765197462,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公布Bezuclastinib在晚期系统性肥大细胞增多症（Advsm）患者中的Apex试验积极顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1180478503","title":"Cogent Biosciences, Inc. - Bezuclastinib试验显示89%的患者骨髓肥大细胞减少≥50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180478503","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180478503?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:33","pubTimestamp":1765197207,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. - Bezuclastinib试验显示89%的患者骨髓肥大细胞减少≥50%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","COGT","BK4139"],"gpt_icon":0},{"id":"1195943636","title":"Cogent Biosciences宣布提议同时公开发行2031年到期可转换高级票据和普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195943636","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195943636?lang=zh_cn&edition=full","pubTime":"2025-11-11 05:02","pubTimestamp":1762808536,"startTime":"0","endTime":"0","summary":"Cogent Biosciences宣布提议同时公开发行2031年到期可转换高级票据和普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","COGT"],"gpt_icon":0},{"id":"1175488357","title":"Cogent Biosciences, Inc.：Wedbush将其评级从中性上调至跑赢大市；目标价格从13美元上调至38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175488357","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175488357?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:10","pubTimestamp":1762787415,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.：Wedbush将其评级从中性上调至跑赢大市；目标价格从13美元上调至38美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1157727526","title":"Cogent Biosciences股份在盘前交易中上涨121%，因其联合药物在晚期试验中减缓癌症进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1157727526","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157727526?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:15","pubTimestamp":1762780558,"startTime":"0","endTime":"0","summary":"Cogent Biosciences股份在盘前交易中上涨121%，因其联合药物在晚期试验中减缓癌症进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1150988897","title":"Cogent Biosciences公布Bezuclastinib高峰期III期临床试验在胃肠道间质瘤中的积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1150988897","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150988897?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:01","pubTimestamp":1762776094,"startTime":"0","endTime":"0","summary":"Cogent Biosciences公布Bezuclastinib高峰期III期临床试验在胃肠道间质瘤中的积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","COGT"],"gpt_icon":0},{"id":"1195113584","title":"Cogent Biosciences, Inc.截至2025年9月30日现金、现金等价物及可交易证券为3.909亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195113584","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195113584?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:03","pubTimestamp":1762178587,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.截至2025年9月30日现金、现金等价物及可交易证券为3.909亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","BK4139","BK4505"],"gpt_icon":0},{"id":"2575200905","title":"Cogent Biosciences, Inc.盘中异动 快速跳水5.25%报15.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575200905","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575200905?lang=zh_cn&edition=full","pubTime":"2025-10-15 01:00","pubTimestamp":1760461216,"startTime":"0","endTime":"0","summary":"北京时间2025年10月15日01时00分，Cogent Biosciences, Inc.股票出现波动，股价快速下挫5.25%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。其相关个股中，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Senti Biosciences, Inc.涨幅较大，Pmgc Holdings Inc.、Astria Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为2800.12%、37.72%、37.14%，振幅较大的相关个股有Pmgc Holdings Inc.、Cdt Equity Inc C/Wts 22/09/2028、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com，振幅分别为55.85%、38.33%、37.50%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501001694c91d11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101501001694c91d11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","COGT"],"gpt_icon":0},{"id":"2518273740","title":"Cogent Biosciences, Inc.盘中异动 早盘快速下挫5.14%报6.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518273740?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:34","pubTimestamp":1741617259,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时34分，Cogent Biosciences, Inc.股票出现异动，股价大幅跳水5.14%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.03%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3473.08%、737.01%、547.82%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223419a26a3cb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223419a26a3cb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","COGT","BK4139"],"gpt_icon":0},{"id":"2517588467","title":"Cogent Biosciences(COGT.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价17.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517588467","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517588467?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:32","pubTimestamp":1741386747,"startTime":"0","endTime":"0","summary":"Cogent Biosciences(COGT.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价17.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08063248605336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COGT"],"gpt_icon":0},{"id":"2517192712","title":"Cogent Biosciences, Inc.盘中异动 股价大跌5.02%报7.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517192712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517192712?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:59","pubTimestamp":1741291182,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时59分，Cogent Biosciences, Inc.股票出现异动，股价大幅下跌5.02%。截至发稿，该股报7.29美元/股，成交量28.4949万股，换手率0.25%，振幅5.35%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.24%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307035942989eecbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307035942989eecbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","COGT","BK4505"],"gpt_icon":0},{"id":"2517173928","title":"Cogent Biosciences, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517173928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517173928?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:42","pubTimestamp":1741200158,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时42分，Cogent Biosciences, Inc.股票出现波动，股价大幅上涨5.02%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.37%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Marker Therapeutics, Inc.涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为952.54%、306.39%、303.63%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Marker Therapeutics, Inc.，振幅分别为82.59%、54.27%、50.73%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306024239a2610cd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306024239a2610cd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COGT","BK4505","BK4139"],"gpt_icon":0},{"id":"1190107990","title":"异动解读 | Cogent Biosciences, Inc.盘中大跌5.05%,暂时原因不明","url":"https://stock-news.laohu8.com/highlight/detail?id=1190107990","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190107990?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:46","pubTimestamp":1741020385,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc.(COGT)今日盘中股价大跌5.05%,引发市场广泛关注。\n根据公开新闻报道,该股盘中出现大幅下跌,最低报7.15美元/股,振幅6.24%。但目前暂时没有明确的消息报道可以解释其股价下跌的具体原因。\n公司主要从事生物技术领域,为遗传定义的疾病开发精准疗法。其主要产品CGT9486是一种旨在抑制导致系统性肥大细胞增多症和晚期胃肠道间质瘤的KIT激酶突变的药物。目前有待进一步关注公司动向,以明确导致股价大幅波动的原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Cogent Biosciences, Inc.盘中大跌5.05%,暂时原因不明","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["COGT"],"gpt_icon":0},{"id":"2516655976","title":"Cogent Biosciences, Inc.盘中异动 临近午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516655976","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516655976?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:36","pubTimestamp":1741019794,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时36分，Cogent Biosciences, Inc.股票出现异动，股价快速下跌5.05%。Cogent Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为3884.93%、173.17%、141.71%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、90.70%、70.53%。Cogent Biosciences, Inc.公司简介：Cogent Biosciences Inc是一家生物技术公司，专注于为遗传定义的疾病开发精准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003635abe65a63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304003635abe65a63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","COGT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogentbio.com","stockEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":-0.0304},{"period":"3month","weight":-0.1022},{"period":"6month","weight":1.7846},{"period":"1year","weight":3.793},{"period":"ytd","weight":-0.0028}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cogent Biosciences, Inc.于2014年3月根据特拉华州法律成立。该公司是一家临床阶段的生物技术公司，专注于开发针对遗传性疾病的精确疗法。该公司的方法是设计合理的精准疗法，治疗疾病的根本原因，改善患者的生活。该公司最先进的项目是bezuclastinib，也称为CGT9486，这是一种高度选择性的酪氨酸激酶抑制剂，旨在有效抑制KIT D816V突变以及KIT外显子17中的其他突变。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.010222},{"month":2,"riseRate":0.25,"avgChangeRate":-0.008843},{"month":3,"riseRate":0.375,"avgChangeRate":-0.060557},{"month":4,"riseRate":0.25,"avgChangeRate":-0.063724},{"month":5,"riseRate":0.625,"avgChangeRate":0.053167},{"month":6,"riseRate":0.625,"avgChangeRate":0.137381},{"month":7,"riseRate":0.75,"avgChangeRate":0.693474},{"month":8,"riseRate":0.625,"avgChangeRate":0.126132},{"month":9,"riseRate":0.375,"avgChangeRate":-0.11087},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011089},{"month":11,"riseRate":0.125,"avgChangeRate":0.046358},{"month":12,"riseRate":0.25,"avgChangeRate":-0.095771}],"exchange":"NASDAQ","name":"Cogent Biosciences, Inc.","nameEN":"Cogent Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cogent Biosciences, Inc.(COGT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cogent Biosciences, Inc.,COGT,Cogent Biosciences, Inc.股票,Cogent Biosciences, Inc.股票老虎,Cogent Biosciences, Inc.股票老虎国际,Cogent Biosciences, Inc.行情,Cogent Biosciences, Inc.股票行情,Cogent Biosciences, Inc.股价,Cogent Biosciences, Inc.股市,Cogent Biosciences, Inc.股票价格,Cogent Biosciences, Inc.股票交易,Cogent Biosciences, Inc.股票购买,Cogent Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cogent Biosciences, Inc.(COGT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cogent Biosciences, Inc.(COGT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}